Xeris Biopharma Holdings Inc (STU:2B30)
€ 7.23 +0.11 (+1.49%) Market Cap: 1.25 Bil Enterprise Value: 1.38 Bil PE Ratio: 137.83 PB Ratio: 110.27 GF Score: 74/100

Xeris Biopharma Holdings Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2026 / 03:30PM GMT
Release Date Price: €4.88 (-0.85%)
Jenna Davidner
Barclays Services Corp - Equity Analyst

All right, I think we're all set. Good morning. Yes, it's still morning. Good morning, and welcome to the Barclays Miami Healthcare Conference. My name's Jenna Davidner. I'm one of the analysts here on the specialty pharmaceuticals team. And on stage with me, I have Xeris Biopharma, and from the company, we have the CEO, John Shannon; and on the end, we have Steve Pieper, the CFO.

Thank you guys for joining, and welcome to the conference.

John Shannon
Xeris Biopharma Holdings Inc - President, Chief Operating Officer

Thanks for having us.

Questions & Answers

Jenna Davidner
Barclays Services Corp - Equity Analyst

So maybe just to level set the conversation, John, can you just give investors that are less familiar a brief overview of the company and your current product portfolio?

John Shannon
Xeris Biopharma Holdings Inc - President, Chief Operating Officer

Yeah, I'll just go really high level

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot